Fabre-Kramer Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Fabre-Kramer Pharmaceuticals is a private, development-stage biotech company with a three-decade legacy in CNS drug development. Its strategy centers on advancing a pipeline of small molecule candidates, primarily for psychiatric indications such as major depressive disorder (MDD) and generalized anxiety disorder (GAD). The company appears to operate with a lean structure, leveraging its deep expertise in CNS pharmacology to navigate clinical development and seek regulatory approvals and/or partnerships. Its success is contingent on positive late-stage clinical data and the ability to secure commercialization pathways.

PsychiatryNeurology

Technology Platform

Medicinal chemistry and pharmacology focused on CNS-active small molecules, with expertise in blood-brain barrier penetration and receptor targeting (e.g., 5-HT1A).

Opportunities

If approved, gepirone ER addresses a multi-billion dollar antidepressant market with a high unmet need for better-tolerated therapies.

A successful regulatory outcome could position the company for a lucrative acquisition or partnership with a larger pharmaceutical firm with commercial infrastructure.

Risk Factors

The company faces extreme regulatory risk following a recent FDA Complete Response Letter for its lead asset.

Its financial viability is heavily dependent on this single program, and it operates in the highly competitive and genericized CNS market.

Competitive Landscape

Fabre-Kramer competes in the massive and crowded antidepressant market, dominated by generic SSRIs/SNRIs and newer branded agents like esketamine and auvelity. Its potential differentiation lies in gepirone's unique 5-HT1A agonist mechanism, aiming for an improved tolerability profile.

More companies in Small Molecule Drugs →More companies in United States →